Study to Evaluate the Immune Responses of Trivalent Cold-Adapted Influenza Vaccine (CAIV-T) Compared With (TIV)

A Prospective, Randomized, Open-Label Study to Evaluate the Immune Responses of Trivalent Cold-Adapted Influenza Vaccine (CAIV-T) Compared With Trivalent Inactivated Vaccine (TIV) in Children 6 to <36 Months of Age

The purpose of this study is to describe the level of serum antibody conferred by CAIV-T and TIV against homotypic and heterotypic influenza virus strains.

Study Overview

• Status: Completed
• Conditions: Influenza
• Intervention / Treatment: Biological: CAIV-T; Other: TIV

• Study Type: Interventional
• Enrollment: 52
• Phase: Phase 2

Contacts and Locations

Study Locations

• United States
  • Utah
    • Layton, Utah, United States, 84041
      • Wee Care Pediatrics
    • Ogden, Utah, United States, 84405
      • Bear Care Pediatrics
    • Pleasant Grove, Utah, United States, 84062
      • Alpine Pediatrics
    • Provo, Utah, United States, 84604
      • Utah Valley Pediatrics
    • South Jordan, Utah, United States, 84095
      • Families First Pediatrics

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 6 months to 3 years (Child)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Male or Female
• Ages 6 to but less than 36 months (reached their 6th month but have not yet reached their 3rd birthday) at the time of randomization
• Written informed consent and Health Insurance Portability and Accountability Act (HIPAA) authorization (if applicable) obtained from the participant's parent/legal representative
• Ability of the parent/legal representative to understand and comply with the requirements of the study
• Parent/legal representative available by telephone
• Ability to complete follow-up period of 180 days after final study vaccination, as required by the protocol

Exclusion Criteria:

• History of hypersensitivity to any component of CAIV-T or TIV, including egg or egg products, monosodium glutamate, porcine gelatin or thimerosal
• History of hypersensitivity to gentamicin
• Any known immunosuppressive condition or immune deficiency disease (including HIV infection), or ongoing receipt of any immunosuppressive therapy
• Household contact who is immunocompromised (participants should also avoid close contact with immunocompromised individuals for at least 21 days after each study vaccination)
• History of Guillain-Barre syndrome
• Medically diagnosed wheezing, bronchodilator use, or steroid use (systemic or inhaled), by parent/legal representative report or chart review, within the 42 days prior to randomization (i.e., children with recent persistent asthma are excluded); or history of severe persistent asthma, according to the criteria described in the National Asthma Education and Prevention Program (NAEPP) Expert Panel Report: Guidelines for the Diagnosis and Management of Asthma - Update on Selected Topics 2002
• Acute febrile (not greater than 100.0 degrees F oral or equivalent) and/or clinically significant respiratory illness (e.g., cough or sore throat) within 72 hours prior to either study vaccination
• Use of aspirin or aspirin-containing products within 30 days prior to randomization, or expected use through 180 days after final study vaccination
• Receipt of any prior influenza vaccine
• Use of anti-influenza medications (including amantadine, rimantadine, oseltamivir, and zanamivir) within 14 days prior to randomization, or expected use through 180 days after final study vaccination
• Administration of any live virus vaccine within 30 days prior to randomization, or expected receipt through 30 days after final study vaccination
• Administration of any inactivated (i.e., non-live) vaccine within 14 days prior to randomization, or expected receipt within 14 days before, or 14 days after, either study vaccination
• Receipt of any investigational agent within 30 days prior to randomization, or expected receipt through 180 days after final study vaccination (use of licensed agents for indications not listed in the package insert is permitted)
• Receipt of any blood product within 90 days prior to randomization, or expected receipt through 180 days after final study vaccination
• Family member or household contact who is an employee of the research center or otherwise involved with the conduct of the study
• Any condition that, in the opinion of the investigator, would interfere with evaluation of the vaccine or interpretation of the study results

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: 1; CAIV-T	Biological: CAIV-T; A total vol. of 0.2 mL will be administered intranasally (approx. 0.1 mL into each nostril)for ea. of two doses.
Other: 2; TIV	Other: TIV; A total vol. of 0.25 will be administered intramuscularly for each of two doeses.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
The following immunogenicity endpoints: The strain-specific HAI seroconversion rates (≥ 4-fold increase) among baseline seronegative participants (HAI titer ≤ 1:4), by dose number	Day 28 post final vaccination
The proportion of participants achieving ≥ 4-fold increase in strain-specific HAI titer from baseline in all participants regardless of baseline serostatus, by dose number	Day 28 post final vaccination

Secondary Outcome Measures

Outcome Measure	Time Frame
Safety endpoints include: AEs SAEs and significant new medical conditions for all participants	Day 28 post vaccination

Collaborators and Investigators

• Sponsor: MedImmune LLC

Study record dates

Study Major Dates

• Study Start: May 1, 2005
• Primary Completion (Actual): January 1, 2006
• Study Completion (Actual): January 1, 2006

Study Registration Dates

• First Submitted: May 23, 2005
• First Submitted That Met QC Criteria: May 23, 2005
• First Posted (Estimate): May 24, 2005

Study Record Updates

• Last Update Posted (Estimate): July 24, 2008
• Last Update Submitted That Met QC Criteria: July 22, 2008
• Last Verified: July 1, 2008

More Information

Terms related to this study

• Additional Relevant MeSH Terms: RNA Virus Infections; Virus Diseases; Infections; Respiratory Tract Infections; Respiratory Tract Diseases; Orthomyxoviridae Infections; Influenza, Human
• Other Study ID Numbers: MI-CP123

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No